Financial reports
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
6 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
22 Mar 24
8-K
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
4 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
22 Jan 24
8-K
Regulation FD Disclosure
18 Dec 23
8-K
Corporate Presentation November 2023
13 Nov 23
8-K
Cara Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
2 Nov 23
8-K
Corporate Presentation August 2023
7 Aug 23
8-K
Cara Therapeutics Reports Second Quarter 2023 Financial Results
7 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
6 Mar 24
S-8
Registration of securities for employees
6 Mar 23
S-3/A
Shelf registration (amended)
9 May 22
S-3
Shelf registration
1 Mar 22
S-8
Registration of securities for employees
1 Mar 22
S-8
Registration of securities for employees
1 Mar 21
S-8
Registration of securities for employees
28 Feb 20
S-8
Registration of securities for employees
20 Nov 19
S-3ASR
Automatic shelf registration
9 Sep 19
424B5
Prospectus supplement for primary offering
25 Jul 19
Proxies
DEFA14A
Additional proxy soliciting materials
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 19
DEF 14A
Definitive proxy
24 Apr 19
Other
EFFECT
Notice of effectiveness
12 May 22
CORRESP
Correspondence with SEC
9 May 22
CORRESP
Correspondence with SEC
26 Apr 22
CORRESP
Correspondence with SEC
22 Apr 22
UPLOAD
Letter from SEC
8 Mar 22
SEC STAFF
SEC staff action: Order
18 Feb 20
SEC STAFF
SEC staff action: Order
5 Feb 20
EFFECT
Notice of effectiveness
5 Apr 19
CORRESP
Correspondence with SEC
2 Apr 19
UPLOAD
Letter from SEC
22 Mar 19
Ownership
4
Scott Terrillion
4 Mar 24
4
Christopher Posner
4 Mar 24
4
Joana Goncalves
4 Mar 24
SC 13G/A
Bain Capital Life Sciences Opportunities III, LP
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Scott Terrillion
12 Feb 24
4
Ryan D Maynard
12 Feb 24
4
Joana Goncalves
12 Feb 24
4
Christopher Posner
12 Feb 24
4
Scott Terrillion
5 Feb 24